Quince Therapeutics announces special shareholder meeting

Quince Therapeutics set a special shareholder meeting for Oct. 6, 2026 via live webcast.

Shareholders will vote on issuing common stock tied to the conversion of Series C Non-Voting Convertible Preferred Stock, warrant exercises, and Orphai Options.

Shareholders will also consider authorizing common stock issuance for the PIPE Preferred Shares and PIPE Warrants.

Other items include increasing authorized common shares to 275,000,000, adopting a 2026 equity incentive plan, and a 2026 ESPP.

The meeting may also seek approval to adjourn or postpone to continue soliciting votes on the share issuance and authorized share increase items.